ライフサイエンスコーパス: osteonectin

1 s between prostate cancer cells and bone via osteonectin.

2 at the mRNA level, including osteocalcin and osteonectin.

3 the invasive in vitro phenotype mediated by osteonectin.

4 antithrombin (TAT), factor V activation, and osteonectin.

5 Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biolo

6 In this study, we show that SPARC/osteonectin, a small ECM-associated matricellular glycop

7 ourteen fragments from known genes including osteonectin (also known as SPARC and BM-40) were identif

8 e differentiation marker osteopontin, Fgfr1, osteonectin and alkaline phosphatase are down-regulated,

9 o structurally unrelated bone-related genes, osteonectin and osteoactivin, acquired a highly invasive

10 Two other genes (e.g., osteonectin and semaphorin 3B) are well characterized as

11 site overlaps those of SPARC (also known as osteonectin) and discodin domain receptor 2, but is more

12 ertain anti-adhesion molecules (versican and osteonectin), and poor in the pro-adhesive molecules ost

13 ulated genes were SNAI2, FGFBP1, VIM, SPARC (osteonectin), and SERPINE1, while the downregulated gene

14 The bone proteins, osteopontin, osteonectin, and bone sialoprotein, were identified in t

15 ences in clotting or product formation (FPA, osteonectin, and factor Va) were observed.

16 steogenic cell lineages including periostin, osteonectin, and Id2 are expressed specifically in the c

17 type I, clusterin, matrix glycoprotein sc1, osteonectin, and one unknown molecule (designated SIM).

18 last differentiation, including osteopontin, osteonectin, and osteocalcin.

19 ike alkaline phosphatase (ALP), osteopontin, osteonectin, and osteocalcin; and late markers like DMP2

20 ssions of alkaline phosphatase, osteocalcin, osteonectin, and osteopontin were analyzed along with in

21 cellular production of proteins osteocalcin, osteonectin, and osteopontin.

22 extracellular matrix protein known as BM-40, osteonectin, and SPARC (secreted protein acidic and rich

23 ecreted protein, acidic and rich in cysteine/osteonectin, and thrombospondin 4.

24 rinogen, von Willebrand factor, factor V and osteonectin are decreased in concentration and significa

25 SPARC, also termed osteonectin, BM-40 and 43K protein, is an acidic, cystei

26 Secreted protein acidic and rich in cysteine/osteonectin/BM-40 (SPARC) is a matrix-associated protein

27 One of its component proteins, SPARC (osteonectin/BM-40), binds calcium and collagens, and can

28 , and the extracellular matrix protein SPARC/osteonectin/BM-40.

29 ells in part by stimulating the secretion of osteonectin by bone.

30 In vitro studies indicate that osteonectin can bind collagen and regulate angiogenesis,

31 ne morphogenetic proteins in an osteocalcein/osteonectin carrier (hBMP/NCP) (n=2 sites).

32 ctivated receptor gamma (PPARgamma), leptin, osteonectin, core binding factor 1 (CBFA1), and FBJ muri

33 Expression of osteonectin did not affect MDA-231 cell proliferation, a

34 ession models involve three key genes-SPARC (Osteonectin), Doublecortex, and Semaphorin3B-which play

35 e.g., alkaline phosphatase, type I collagen, osteonectin) during days 3-7, and the concomitant format

36 xpressing osteonectin to examine the role of osteonectin expression in breast cancer cells and its ef

37 Interestingly, high osteonectin expression in MDA-231 cells inhibited metast

38 d platelet aggregation in vitro and the high osteonectin expression in MDA-231 cells reduced tumor ce

39 d selected animal models for bone fragility, osteonectin expression is decreased.

40 Osteonectin expression was not blocked when melanoma cel

41 se (ALP), in vitro mineralization along with osteonectin expression, induction of apoptosis, and cyto

42 ly demonstrated that expression of the SPARC/osteonectin gene, while undetectable in the MCF7 cell li

43 tein components of bone matrix, collagen and osteonectin, have been shown to be substrates of the act

44 To determine the function of osteonectin in bone, we used contact x-ray, histomorphom

45 he expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic

46 s suggest that high endogenous expression of osteonectin in breast cancer cells may reduce metastasis

47 e up-regulated expression of VE-cadherin and osteonectin in breast tumor vasculature.

48 ecreted protein acidic and rich in cysteine)/osteonectin in insulin resistance but potential effects

49 n (statistically significant at P <0.01) and osteonectin in PDL cells relative to stimulation with do

50 We further show that recombinant osteonectin increased the invasiveness of PC-3 cells, wh

51 However, in vitro invasion of these osteonectin-infected cells through Matrigel and colony f

52 et-tumor cell aggregation, because exogenous osteonectin inhibited platelet aggregation in vitro and

53 d protein acidic and rich in cysteine)/BM 40/osteonectin is a matricellular protein shown to function

54 Osteonectin is abundant in bone and is expressed in area

55 Increased expression of osteonectin is found in malignant breast tumors.

56 BM-40 (also known as SPARC or osteonectin) is an anti-adhesive secreted glycoprotein i

57 ed protein, acidic and rich in cysteine), or osteonectin, is a matricellular protein.

58 ne (SPARC), originally discovered in bone as osteonectin, is a mediator of collagen deposition and pr

59 ased the invasiveness of PC-3 cells, whereas osteonectin-neutralizing antibodies blocked this p45-sEr

60 We found that osteonectin-null mice have decreased bone formation and

61 is to characterize the skeletal phenotype of osteonectin-null mice.

62 for osteoclasts; and the mineral regulators osteonectin (ON) and matrix Gla protein (MGP).

63 The region in human osteonectin (ON) responsible for binding to type V colla

64 Here we examined the effects of osteonectin (ON), a major factor secreted by SCs, on sur

65 alcin (OCN), alpha 2(1)(type 1) collagen and osteonectin (ON), were performed.

66 in, acidic and rich in cysteine, also called osteonectin or BM40), and collagen IV decreased, and fib

67 examination of tumor cells expressing either osteonectin or osteoactivin revealed that there was no i

68 e that the extracellular matrix glycoprotein osteonectin or secreted protein acidic and rich in cyste

69 lation of alkaline phosphatase, osteocalcin, osteonectin/osteopontin, and in vitro mineralized nodule

70 ghly abundant primary transcripts, including osteonectin, RACK1, calnexin, calreticulin, FTL, and B2M

71 y, Material 1 and Material 2 elicited higher osteonectin release than Material 3 and Material 4 which

72 Differences in platelet activation (osteonectin release) between normal and factor VIII-defi

73 prothrombin fragments, platelet activation (osteonectin release), factor Va generation, fibrinopepti

74 ests the latter products suppress endogenous osteonectin secretion.

75 ells of the new bone were positive for human osteonectin showing their donor origin.

76 SPARC/Osteonectin (SP/ON) is implicated in the regulation of c

77 ine phosphatase (ALPL), osteocalcin (BGLAP), osteonectin (SPARC) and osteopontin (SPP1) were detected

78 Osteonectin (SPARC, BM-40) is a bone matrix factor that

79 the secreted protein, acidic, cysteine-rich (osteonectin) (SPARC) gene, which encodes a matricellular

80 Deletion of osteonectin/SPARC causes age-onset cataract in mice and

81 Osteonectin/SPARC expression and/or secretion was monito

82 Western blot analysis revealed osteonectin/SPARC in both the macula and the peripheral

83 is study, the expression and localization of osteonectin/SPARC in the monkey retina were determined a

84 The expression pattern of osteonectin/SPARC in the subcellular retinal fractions i

85 Osteonectin/SPARC is a secreted protein that has been im

86 thern blot analysis shows that in the retina osteonectin/SPARC is expressed almost exclusively by the

87 cultured on porous substrates indicated that osteonectin/SPARC is secreted in large amounts from both

88 ollectively these data provide evidence that osteonectin/SPARC is synthesized in the macular RPE, sec

89 Outside of the retina osteonectin/SPARC mRNA is broadly expressed in many huma

90 Immunohistochemical analysis localized osteonectin/SPARC specifically to the outer plexiform la

91 n subcellular fractions of the whole retina, osteonectin/SPARC was detected, mainly in the soluble fr

92 ents, proteinases and inhibitors, galectins, osteonectin/SPARC, and prostaglandin D2 synthase.

93 at p45-sErbB3 up-regulated the expression of osteonectin/SPARC, biglycan, and type I collagen in calv

94 portion of SC1/ECM2 has sequence homology to osteonectin/SPARC, the unique N-terminal one fifth of th

95 ular calcium-binding protein 1 (SMOC1) is an osteonectin/SPARC-related matricellular protein, whose e

96 ctous human lens has increased expression of osteonectin/SPARC.

97 Because osteonectin specifically enhances matrix metalloprotease

98 These data indicate that osteonectin supports bone remodeling and the maintenance

99 ell-conditioned medium is a low glycosylated osteonectin that specifically promotes the invasive abil

100 trix proteins (osteopontin, osteocalcin, and osteonectin) that regulate skeletal mineralization may o

101 t cancer cells with an adenovirus expressing osteonectin to examine the role of osteonectin expressio

102 bone is, in part, mediated by the ability of osteonectin to promote migration, protease activity, and

103 Expression of osteonectin was also associated with reduced adhesion to

104 Induction of osteonectin was confirmed by Northern and Western blot a

105 (panstromal expression), whereas the second (osteonectin) was specifically expressed within the juxta

106 steoblast promoters, such as osteopontin and osteonectin, was less sensitive to changes in gap juncti

107 >10 ng/mL, ALP, in vitro mineralization, and osteonectin were downregulated in PDL cells.

108 factor V activation, and release of platelet osteonectin were slower in factor XI-deficient blood tha

109 ncluding laminin, J6(Hsp 47), and J31(SPARC, osteonectin) were expressed at lower levels in RA-treate

110 essed lower levels of matrix Gla protein and osteonectin, whereas alkaline phosphatase, bone sialopro